Comparative Pharmacology
Head-to-head clinical analysis: NEOPASALATE versus PARASAL SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEOPASALATE versus PARASAL SODIUM.
NEOPASALATE vs PARASAL SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Para-aminosalicylic acid (PAS) competitively inhibits the conversion of aminobenzoic acid to dihydrofolate, thereby inhibiting Mycobacterium tuberculosis growth.
Parasal sodium is a prodrug that is converted to 5-aminosalicylic acid (5-ASA) in the colon, where it inhibits cyclooxygenase and lipoxygenase pathways, reducing prostaglandin and leukotriene synthesis, thereby exerting anti-inflammatory effects in the gastrointestinal tract.
4-6 g orally twice daily; maximum 12 g/day.
300 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life is 2.5–4.5 hours in adults, prolonged in renal impairment.
2-3 hours for low doses (antiplatelet effect); 15-30 hours for high doses (anti-inflammatory), increasing with dose due to saturation of hepatic metabolism.
Primarily renal (≥80% as unchanged drug and acetylated metabolite); minor fecal elimination (<5%).
Primarily renal (90-95% as unchanged drug and metabolites, with 50-70% as unchanged salicylate in alkaline urine); minor biliary (2-5%) and fecal (<1%).
Category C
Category C
Antituberculosis Agent
Antituberculosis Agent